1. 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. (9th November 2020) Authors: Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Kelley, Heather;... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Issue 10 (30th June 2016) Authors: Anderson, Peter M.; Bielack, Stefan S.; Gorlick, Richard G.; Skubitz, Keith; Daw, Najat C.; Herzog, Cynthia E.; Monge, Odd R.; Lassaletta, Alvaro; Boldrini, Erica; Pápai, Zsuzanna; Rubino, Joseph; Pathiraja, Kumudu; Hille, Darcy A.; Ayers, Mark; Yao, Siu‐Long; Nebozhyn, Michael; Lu, Brian; Mauro,... Journal: Pediatric blood & cancer Issue: Volume 63:Issue 10(2016) Page Start: 1761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer. (4th November 2015) Authors: Ghamande, Sharad; Mauro, David; Price, Cheryl; Wheatley, Donna; Janik, John; Khleif, Samir N Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer. Issue 2 (December 2015) Authors: Ghamande, Sharad; Mauro, David; Price, Cheryl; Wheatley, Donna; Janik, John; Khleif, Samir Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. (15th April 2020) Authors: Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Interjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Bao, Riyue; Wein... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. (4th November 2015) Authors: Haas, Naomi B; Stein, Mark N; Tutrone, Ronald; Perini, Rodolfo; Denker, Andrew; Mauro, David; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. Issue 2 (December 2015) Authors: Haas, Naomi; Stein, Mark; Tutrone, Ronald; Perini, Rodolfo; Denker, Andrew; Mauro, David; Fong, Lawrence Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. (4th November 2015) Authors: Cohen, Ezra EW; Moore, Kathleen N; Slomovitz, Brian M; Chung, Christine H; Anderson, Matthew L; Morris, Shannon R; Mauro, David; Burtness, Barbara Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. Issue 2 (December 2015) Authors: Cohen, Ezra; Moore, Kathleen; Slomovitz, Brian; Chung, Christine; Anderson, Matthew; Morris, Shannon; Mauro, David; Burtness, Barbara Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The Plume Chaser mission: Two-spacecraft search for organics on the dwarf planet Ceres. Issue 5 (1st March 2016) Authors: Nayak, Michael; Mauro, David; Stupl, Jan; Aziz, Jonathan; Colaprete, Anthony; Dono-Perez, Andres; Frost, Chad; Jonsson, Jonas; McKay, Chris; Sears, Derek; Soulage, Michael; Swenson, Jason; Yang, Fan Yang Journal: Advances in space research Issue: Volume 57:Issue 5(2016) Page Start: 1133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗